|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> The synergistic effects, such as a higher inhibition rate, and lower expressions of MRP1 and VEGF, of combined curcumin and LFLIU against glioma was much better than that of a single treatment.
|
31190861 |
2019 |
|
Glioma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Effective treatment for glioma is challenging, which can be in part due to prolonged chemotherapy leading to mutations in genes associated with multi-drug resistances (MRP1, Bcl-2, and ABC family).
|
31129471 |
2019 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our results provide strong evidence that the MDM4 gene is tightly linked to genetic susceptibility for non-GBM risk in Han Chinese population, indicating a important role for MDM4 gene in the etiology of glioma.
|
30038284 |
2018 |
|
Glioma
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.
|
28346443 |
2017 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Therefore, our results suggest that there is a potential nexus of Shh-Gli1-BMI1 cell signaling to regulate MRP1 and to promote chemoresistance in glioma.
|
27662839 |
2016 |
|
Glioma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
An MDM4 mutation identified in a glioma patient was associated with loss of the putative MDM4 target site.
|
26028311 |
2015 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrated that silencing of AGPS in chemotherapy resistance glioma U87MG/DDP and hepatic carcinoma HepG2/ADM cell lines resulted in reduced cell proliferation, increased drug sensitivity, cell cycle arrest and cell apoptosis through reducing the intracellular concentration of lysophosphatidic acid (LPA), lysophosphatidic acid-ether (LPAe) and prostaglandin E2 (PGE2), resulting in reduction of LPA receptor and EP receptors mediated PI3K/AKT signaling pathways and the expression of several multi-drug resistance genes, like MDR1, MRP1 and ABCG2.
|
24815474 |
2014 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our data indicate that the novel variant MDM4-B may play a role in glioma tumorigenesis or cancer progression.
|
23994448 |
2013 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (25 glioma specimens) showed expression of GST-pi (66.7% of cases), MRP1 (51.3%), MRP5 (45.8%), Pgp (34.8%) and MRP3 (29.9%) in tumor cells.
|
16193381 |
2005 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
LHGDN |
Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target.
|
12640683 |
2003 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
It has been shown that the Hdmx gene is amplified in a subset of gliomas, but thus far, no data are available on HDMX protein expression in tumor cells.
|
11280734 |
2001 |
|
Glioma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We investigated a series of 208 gliomas (106 glioblastomas, 46 anaplastic gliomas, and 56 low-grade gliomas) and identified 5 tumors (4 glioblastomas and 1 anaplastic oligodendroglioma) with MDM4 amplification and overexpression.
|
10626796 |
1999 |